Skip to main content

CytomX Therapeutics, Inc.

corporate_fare Company Profile

CytomX Therapeutics, Inc.

CTMX·NASDAQ·Life Sciences·CIK 0001501989

CytomX is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. The company specializes in conditionally activated, masked biologic therapies using its PROBODY technology platform. This platform uses knowledge of tumor-associated enzymes called proteases. The masking strategy aims to reduce a therapeutic's binding to targets until proteases in the tumor microenvironment remove the mask, allowing for more selective tumor targeting and improving the predicted therapeutic index of drug candidates. CytomX has applied its PROBODY platform for over 15 years, resulting in a pipeline of clinical-stage and pre-clinical stage programs. When designing PROBODY therapeutics, the company considers drug targets previously validated for anti-tumor activity but limited by expression and toxicity in healthy tissues. They also evaluate the clinical unmet need that could be addressed by systemic, masked targeting, and the effector mechanism, applying the PROBODY platform to modalities like antibody drug conjugates ("ADCs"), T-cell engagers ("TCEs"), and cytokines. The goal is to align the indication with the most validated drug modality and cancer cell killing mechanism. CytomX's two current clinical programs, varsetatug masetecan ("Varseta-M") and CX-801, are in Phase 1 clinical development. Varseta-M is an investigational, conditionally activated antibody-drug conjugate ("ADC") targeting epithelial cell adhesion molecule ("EpCAM").

CytomX Therapeutics, Inc. (NASDAQ:CTMX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 20 items for CTMX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-27, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for CTMX spans 8-K, 10-Q, PRE 14A, 424B5.

Recent high-impact activity:

  • FDA Grants Fast Track to CytomX's Varseta-M for Colorectal Cancer
  • Varseta-M Phase 1 Enrollment Complete, Data by Year-End; Q2 Revenue Plunged 92%
  • CytomX Q2 Revenue Plunges to $1.42M, Missing Estimates by 88%
  • CytomX Q2 2026: Cash Runway to H2 2028, Varseta-M Registrational Study Planned for 1H 2027
  • CytomX Q2 2026: Cash Runway to H2 2028, Regeneron Deal Expanded, Varseta-M Dose Optimization Complete

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$76.2M
Net Income
-$17.37M
Op. Cash Flow
-$75.59M
Free Cash Flow
-$75.81M
Operating Income
-$22.36M
Cash & Equivalents
$12.67M
Debt / Equity
0.00×
Net Margin
-22.8%
Shares Outstanding
170.19M sh
Source: 10-K · filed 2026-03-16 · accession 0001193125-26-107146

Short Interest & Short Volume

11.99 days to cover

FINRA reported short interest of 45,246,966 shares in CTMX as of the October 30, 2026 settlement, a 5.7% increase from the prior period — about 12.0 days to cover at its recent average daily volume. On November 20, 2026, 67.7% of CTMX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)45,246,966 shares as of October 30, 2026
Change vs prior period▲ 5.7%
Days to cover11.99 at avg daily volume of 3,772,440
Daily short volume (FINRA facilities)67.7% of 2,470,184 shares on November 20, 2026
5-day average short volume58.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with C →
$2.04 +0.65% today
52-week range · as of 2026-08-06 $1.72 – $8.21
Market cap
$442.55M
Volume
4.9M (1.0× avg)
3-mo avg 4.8M
Live data · 2026-11-22 09:01 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CTMX - Latest Insights

CTMX
Aug 27, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.48
Real-time Price: $2.04 info
Change: -$1.44 (-41%) info
Market Cap: $442.55M info
CTMX
Aug 10, 2026, 7:37 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $3.48
Real-time Price: $2.04 info
Change: -$1.44 (-41%) info
Market Cap: $442.55M info
CTMX
Aug 06, 2026, 6:05 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $3.38
Real-time Price: $2.04 info
Change: -$1.34 (-40%) info
Market Cap: $442.55M info
CTMX
Aug 06, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.37
Real-time Price: $2.04 info
Change: -$1.33 (-39%) info
Market Cap: $442.55M info
CTMX
Aug 06, 2026, 4:05 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $3.26
Real-time Price: $2.04 info
Change: -$1.22 (-37%) info
Market Cap: $442.55M info
CTMX
Jun 22, 2026, 4:52 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.04
Real-time Price: $2.04 info
Change: -$0.9969 (-33%) info
Market Cap: $442.55M info
CTMX
Jun 03, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $3.22
Real-time Price: $2.04 info
Change: -$1.18 (-37%) info
Market Cap: $442.55M info
CTMX
Jun 03, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $3.27
Real-time Price: $2.04 info
Change: -$1.23 (-38%) info
Market Cap: $442.55M info
CTMX
May 07, 2026, 4:12 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.99
Real-time Price: $2.04 info
Change: -$1.95 (-49%) info
Market Cap: $442.55M info
CTMX
May 07, 2026, 4:11 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $4.19
Real-time Price: $2.04 info
Change: -$2.15 (-51%) info
Market Cap: $442.55M info
CTMX
May 07, 2026, 4:06 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.00
Real-time Price: $2.04 info
Change: -$1.96 (-49%) info
Market Cap: $442.55M info
CTMX
Apr 20, 2026, 4:15 PM EDT
Filing Type: PRE 14A
Importance Score:
9
Price at Filing: $4.88
Real-time Price: $2.04 info
Change: -$2.84 (-58%) info
Market Cap: $442.55M info
CTMX
Mar 19, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $4.83
Real-time Price: $2.04 info
Change: -$2.78 (-58%) info
Market Cap: $442.55M info
CTMX
Mar 16, 2026, 4:37 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $6.66
Real-time Price: $2.04 info
Change: -$4.62 (-69%) info
Market Cap: $442.55M info
CTMX
Mar 16, 2026, 4:04 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $6.74
Real-time Price: $2.04 info
Change: -$4.70 (-70%) info
Market Cap: $442.55M info
CTMX
Mar 16, 2026, 4:01 PM EDT
Filing Type: S-3ASR
Importance Score:
7
Price at Filing: $6.65
Real-time Price: $2.04 info
Change: -$4.61 (-69%) info
Market Cap: $442.55M info
CTMX
Mar 16, 2026, 7:05 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $6.56
Real-time Price: $2.04 info
Change: -$4.52 (-69%) info
Market Cap: $442.55M info
CTMX
Mar 16, 2026, 7:04 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $7.69
Real-time Price: $2.04 info
Change: -$5.65 (-73%) info
Market Cap: $442.55M info
CTMX
Mar 16, 2026, 7:01 AM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $5.92
Real-time Price: $2.04 info
Change: -$3.88 (-65%) info
Market Cap: $442.55M info
CTMX
Mar 13, 2026, 8:34 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $4.94
Real-time Price: $2.04 info
Change: -$2.90 (-59%) info
Market Cap: $442.55M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets